CTNM
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ · USHealthcareBiotechnology
$13.53-4.92%
Price as of Jul 20, 2026
CTNM growth
Contineum Therapeutics, Inc. Class A Common Stock growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- —
- EBITDA
- -17.3%
- EBIT
- —
- EPS
- +3.5%
- Free cash flow
- -45.8%
- Operating cash flow
- -46.0%
Forward estimates
- Revenue
- —
- EBITDA
- +108.4%
- EPS
- +4.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -42.0%
- EBIT
- -33.7%
- Net income
- -41.9%
- EPS
- -33.1%
- Free cash flow
- -66.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.